UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000042944 |
|---|---|
| Receipt number | R000048562 |
| Scientific Title | The immunological analyses of human peripheral blood mononuclear cells. |
| Date of disclosure of the study information | 2021/01/10 |
| Last modified on | 2025/01/11 09:13:14 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The immunological analyses of human blood cells.
Acronym
The analyses of human blood cells.
Scientific Title
The immunological analyses of human peripheral blood mononuclear cells.
Scientific Title:Acronym
The analyses of human peripheral blood mononuclear cells.
Region
| Japan |
Condition
Condition
Healthy donners
Classification by specialty
| Clinical immunology |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
This study is to investigate the immune response of human peripheral blood mononuclear cells. Cells are subjected to protein expression analyses, gene expression analyses, epigenetic analyses, and in vitro culture experiments.
Basic objectives2
Others
Basic objectives -Others
Immunology research
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
The analyses of gene expression, protein expression, and epigenetic modifications.
Key secondary outcomes
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Persons who do not have any diseases which require treatments.
Key exclusion criteria
Persons who have diseases.
Persons who drowned blood within two weeks.
Persons who do not agree with this study.
Target sample size
60
Research contact person
Name of lead principal investigator
| 1st name | Hiroshi |
| Middle name | |
| Last name | Nakajima |
Organization
Chiba University Graduate School of Medicine
Division name
Department of Allergy and Clinical Immunology
Zip code
260-8670
Address
1-8-1 Inohoana, Chuo-ku, Chiba, Chiba
TEL
043-226-2198
nakajimh@faculty.chiba-u.jp
Public contact
Name of contact person
| 1st name | Shigeru |
| Middle name | |
| Last name | Tanaka |
Organization
Chiba University Graduate School of Medicine
Division name
Department of Allergy and Clinical Immunology
Zip code
260-8670
Address
1-8-1 Inohoana, Chuo-ku, Chiba, Chiba
TEL
043-226-2198
Homepage URL
stanaka@chiba-u.jp
Sponsor or person
Institute
Chiba University
Institute
Department
Personal name
Funding Source
Organization
Ministray of Education, Culture, Sports, Science and Technology
Organization
Division
Category of Funding Organization
Japanese Governmental office
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Chiba University Graduate School of Medicine, Ethics Committe
Address
1-8-1 Inohoana, Chuo-ku, Chiba, Chiba
Tel
043-226-2462
inohana-rinri@chiba-u.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2021 | Year | 01 | Month | 10 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2021 | Year | 01 | Month | 10 | Day |
Date of IRB
| 2021 | Year | 01 | Month | 04 | Day |
Anticipated trial start date
| 2021 | Year | 01 | Month | 11 | Day |
Last follow-up date
| 2025 | Year | 03 | Month | 31 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
this study aim to analyze PBMC from healthy donners.
Management information
Registered date
| 2021 | Year | 01 | Month | 08 | Day |
Last modified on
| 2025 | Year | 01 | Month | 11 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048562
